Table 3.

Prognostic Effects of Progesterone-Receptor Status in Women with Synchronous Breast Cancers, SEER 1998-2005

	Overall Survival
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	Model 1, HR (95% CI)^b		Model 2, HR (95% CI)^c
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	≤ 5 years	> 5 years	≤ 5 years	> 5 years

+/+	2930	2415	966	4.4	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
Discordant	816	613	316	5.6	1.42 (1.19-1.69)	0.95 (0.76-1.20)	1.11 (0.90-1.37)	0.97 (0.75-1.24)
−/−	657	456	286	6.4	1.77 (1.48-2.12)	0.93 (0.72-1.20)	1.08 (0.84-1.38)	1.04 (0.77-1.40)
P value					<0.0001	0.81	0.58	0.92

	Breast Cancer-Specific Survival
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	Model 1, HR (95% CI)^b		Model 2, HR (95% CI)^c
Progesterone-receptor status	No. of patients	No. of patients at year 5	No. of events	Rate^a	≤ 5 years	> 5 years	≤ 5 years	> 5 years

+/+	2930	2415	390	1.8	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
Discordant	816	613	155	2.7	1.75 (1.36-2.24)	1.00 (0.70-1.44)	1.15 (0.85-1.56)	1.04 (0.69-1.55)
−/−	657	456	177	3.9	2.41 (1.89-3.06)	1.09 (0.76-1.57)	1.22 (0.86-1.72)	1.20 (0.76-1.89)
P value					<0.0001	0.89	0.47	0.74

Abbreviations: HR, hazard ratio; CI, confidence interval

Death rate per 100 person-years

Adjusted in a piecewise Cox model for age at diagnosis, race/ethnicity, marital status, AJCC stage, grade, histology of both cancers, surgery type, radiotherapy, and time interval between the two cancers

Adjusted for estrogen-receptor status of both cancers and all variables in Model 1

P value is from the omnibus test of comparing three groups in Cox model